Elevance Health Inc. (ELV) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Elevance Health Inc. (ELV) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How ELV Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $199.13B | 89.4% | 3.6% | $5.66B | $3.17B | 8.7% |
| FY 2024 | $177.01B | 88.8% | 4.4% | $5.98B | $4.55B | 10% |
| FY 2023 | $171.34B | 44% | 5% | $5.99B | $350.7M | 5.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ELV)
- ✓Live walkthrough of ELV's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ELV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELV. Explore sector supply chains on /butterfly.
ELV Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Elevance Health Inc. (ELV)?
In FY 2025 (10-K), ELV converted $199.1B of revenue into a 89.4% gross margin, 3.6% operating margin, and $3.2B in free cash flow (1.6% FCF margin).